Xoma, a biotechnology company often labeled as a ‘zombie’ due to its dwindling market value, has announced its intent to acquire Generation Bio, a developer of gene therapies. This acquisition comes at a time when Generation Bio has struggled significantly since its public debut in 2020, losing most of its market capitalization and facing challenges in advancing its delivery technology, which had previously shown promise in preclinical studies.
The implications of this acquisition are multifaceted. For Xoma, this move could represent a strategic pivot to rejuvenate its portfolio and leverage Generation Bio’s innovative gene therapy platform. However, the acquisition also raises questions about the viability of Generation Bio’s technology and whether Xoma can successfully integrate and advance these assets in a competitive landscape where gene therapy is rapidly evolving. As the industry watches closely, the outcome of this acquisition could set a precedent for similar transactions in the biotech sector.
Open the full market picture for your next decision →
